Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Coppola, Nicola
ASUCOV, NCT05639192: Asunercept for the Treatment of Patients With Moderate to Severe COVID-19 Disease	Terminated	3	34	Europe, RoW	Asunercept, Placebo	Apogenix GmbH	COVID-19	08/23	08/23
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia	Terminated	3	409	Europe, US, RoW	Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo	Dompé Farmaceutici S.p.A	Infectious Pneumonia, Severe COVID-19	09/24	09/24
OASIS, NCT05101187: Olorofim Aspergillus Infection Study	Recruiting	3	225	Europe, Canada, Japan, US, RoW	Olorofim, Olorofim (F901318), AmBisome®, AmBisome® (liposomal amphotericin B)	F2G Biotech GmbH, Iqvia Pty Ltd, Shionogi	Invasive Aspergillosis	09/25	11/26
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B	Active, not recruiting	3	871	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Chronic Hepatitis B, Hepatitis B, Chronic	11/25	05/26
B-Focus, NCT06497504: Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection	Recruiting	2	150	Europe, Canada, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline	Hepatitis B	01/27	05/27
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)	Recruiting	2	280	Europe, Canada, Japan, US, RoW	Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo	GlaxoSmithKline	Chronic Hepatitis B Virus Infection, Hepatitis B	10/27	10/27
NCT06539052: MIGrant Reflex Test HDV (MIGRED) Project	Not yet recruiting	N/A	7500	NA	anti-HDV positive with the reflex testing methodology	University of Campania Luigi Vanvitelli, Gilead Sciences	Hepatitis D Virus Infection	06/26	12/26